Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
N-Alkyl dimethyl benzyl ammonium chloride (C12–C18), also known as ADBAC or benzalkonium chloride with C12 to C18 alkyl chains, is a quaternary ammonium compound widely used as a disinfectant and antimicrobial agent. It acts primarily by disrupting the cell membranes of microorganisms—its cationic surfactant structure binds to and destabilizes lipid bilayers in bacterial and fungal cells—leading to leakage of cellular contents and cell death. Its biocidal activity is chain-length dependent; derivatives with C12 and C14 chains are particularly effective against bacteria and fungi. This compound is found in surface disinfectants for healthcare settings, food processing environments, household cleaning products such as wipes and sprays, as well as some personal care items like hand sanitizers. It is active against a broad spectrum of bacteria (especially gram-positive), some viruses and fungi but not bacterial spores[2][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on N-alkyl dimethyl benzyl ammonium chloride (C12-C18).